Good morning. My name is Juan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Signify Health fourth quarter 2021 earnings conference call. All lines have been placed on mute to prevent any background noise. After the speaker remarks, there will be a question- and- answer session. If you would like to ask a question during this time, simply press Star followed by number one on your telephone keypads. If you would like to withdraw your question, please press Star followed by number two. Thank you. At this time, I will hand over to your host, Jennifer DiBerardino, Head of Investor Relations. Jennifer, you may begin your conference. Good morning, and welcome to Signify Health's fourth quarter and full year 2021 earnings conference call. This call is being webcast live and a recording will be available on the events page of our investor website at signifyhealth.com through May 3rd, 2022. Throughout the call this morning, we will be referencing the financial tables that appeared in our press release dated March 2nd, 2022. In addition, the fourth quarter and full- year 2021 earnings call summary slide presentation we have posted to the events page of the IR website. This morning, we will discuss Signify Health's business outlook, and we will also make certain statements about our future performance, including projections about our future financial performance, our anticipated growth strategies, anticipated trends in our business, and our outlook, including estimates for total GAAP revenue, total adjusted EBITDA, in-home evaluations, bundled payment program size, and bundled payment weighted average savings rate. These statements are only predictions based on our current expectations and projections about future events and constitute forward-looking statements within the meaning of the federal securities laws. There are important factors that could cause our actual results, level of activity, performance, or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Please note the cautionary language about our forward-looking statements as presented in our earnings press release and in our Annual Report on Form 10-K, which will be filed later today. That same cautionary language applies to the statements made in this conference call. We will also discuss certain non-GAAP financial measures, including adjusted EBITDA and adjusted EBITDA margin. Reconciliations to the relevant GAAP numbers for these non-GAAP measures are included in the earnings release filed on Form 8-K yesterday and also in our Form 10-K, which will be filed later today. As a reminder, we intend to participate in industry or sell-side sponsored conferences. In lieu of issuing a press release to announce each conference, we will be posting our conference attendance on the events page and calendar of our investor relations site at signifyhealth.com. I encourage you to register for alerts on the investor site so that you receive an email notification each time we add a conference, other event, or other updates to the investor relations calendar. Joining me on the call today are Kyle Armbrester, Chief Executive Officer, and Steve Senneff, President and Chief Financial Officer. Kyle will provide a business overview, followed by Steve with a financial overview. We will have an operator facilitated question- and- answer session after our prepared remarks. Now I will turn the call over to Kyle. Thank you, Jennifer. Good morning, and thank you for joining us. As I sit here this morning and reflect on the past 14 months, I am proud of and thankful for all we've achieved. We successfully managed through another year of the pandemic, and we continue to evolve with our clients as they turn to us to support them in new ways. Our accomplishments were many, and to name a few, we were recognized by Fast Company's annual list of the World's Most Innovative Companies. We launched new products and programs like Transition to Home and our partnership program, and we continued to successfully execute operationally to exceed our financial targets each quarter. On Tuesday, we closed on our first significant acquisition as a public company of Caravan Health, a leader in enabling accountable care organizations, or ACOs, to excel in population health management and value-based payment programs. We went through a robust diligence process to find Caravan and feel this is a great match as they share our passion for partnering with provider organizations to share risk and drive better patient outcomes. While a lot changed for Signify in 2021, what remained constant is our dedication to driving forward our vision of transforming the U.S. healthcare system from fee-for-service to value-based payment. Yesterday evening, we announced our financial results for the fourth quarter and full- year 2021 and guidance for another strong year in 2022. For 2021, revenue grew by a strong 27% to $773 million and adjusted EBITDA increased 37% to $171 million from a year ago, largely driven by our in-home evaluation or IHE volume growth in our Home and Community Service segment or HCS. For 2021, we performed over 1.9 million IHEs, reflecting significant expansion with our clients that will continue to drive IHE volume growth into 2022 and beyond. Results in our episodes of care or ECS segment for 2021 reflected the ongoing impact of COVID-19 with its variants driving pressure in program size and savings rate. We expect these impacts to lessen over time as COVID cases continue to decline, but we have factored in some ongoing impact into our 2022 outlook. We are proud of our significantly improved outcomes we've helped to achieve for beneficiaries and the savings we've generated for our provider partners in the BPCI-A program and with our commercial clients. Provider partners are committed to bundled payment programs, and we believe CMMI is also committed and will announce a new iteration for 2024 within the next 12 months. We are very excited about the opportunity we have with Caravan Health and our ongoing efforts to expand our reach in value-based care. The combination enhances the value proposition to providers as our services will have a multi-payer applicability to a larger portion of a provider's panel. By multi-payer, we're referring to our deep relationships and existing contracts with private insurers and state and federal governments. A strategic focus for Signify Health has always been driving more participation and success in value-based payment arrangements by integrating episodes of care into total cost of care models. Episodes of care help providers manage the cost of specialist care within total cost of care models. We believe these two payment models are synergistic and help maximize total savings and clinical outcomes. We view the highly anticipated CMS announcement last week about a refinement of the direct contracting model, now called ACO, Realizing Equity, Access, and Community Health, or REACH, as extremely favorable to a combined Signify Caravan business model. ACO REACH is tightly linked to achieving improvements in clinical outcomes by addressing social determinants of health and reducing inequities. The REACH approach is consistent with other ACO models and will extend the pathway for providers to assume total accountability for the quality and cost of their patients' care. Signify's in-home evaluations are specifically designed to collect social determinants of health data and enable the connection of patients to services. Together with Caravan, we believe we have the right set of capabilities to meet all of the model requirements set forth by CMS. Models such as the Medicare Shared Savings Program and REACH create important stepping stones along the pathway for primary care practices. We've recommended to CMS a model focused on chronic condition bundles that would complement MSSP and REACH and provide specialty providers a similar stepping stone to risks and rewards of advanced alternative payment models. Participation by all providers, primary care and specialty, is essential to achieving the Innovation Center's goal of all patients being aligned to an accountable relationship by 2030. We believe no organization is better suited to achieve CMS's goals than Signify Health. We look forward to a successful integration of Caravan Health into our operations and the ability to provide another complementary value-based model to our client base while expanding our provider networks across both lines of business, episodes, and ACOs. Turning to Home and Community Services, 2021 was a great year for the business, and we believe the momentum we have will carry forward into 2022. The value of our in-home evaluations for both our customers and Medicare Advantage members remains meaningful. Customers have asked us to do more, and one of several ways we are meeting that demand is through our partnership program we announced in January. We believe in connecting individuals to the right follow-on care, whether that's seeing their primary care physician or a behavioral health provider after the in-home visit or activating home care, transportation, or food assistance after an acute episode. Developing a partner ecosystem with solutions that connect care and drive alignment among providers is critical for us to deliver a more integrated experience. For our partners, we provide an opportunity to accelerate innovation through a platform that is projected to engage more than 2 million people this year through our IHEs. Additionally, partners have an opportunity to participate in the episode of care programs we manage. Our initial focus is on partner technologies and services that support behavioral health, remote patient monitoring, social determinants of health, member engagement, distribution channels to employers, and care optimization. We're proud to work with our partners who share a vision and are eager to see innovation resulting from this program. Given investor focus on possible regulatory scrutiny of in-home evaluation work since the OIG report last September, we would like to note that the recently released Medicare Advantage Rules Part 1 and 2 contain no reference to in-home evaluations and no proposed changes that would negatively impact our business model. We also see the CMS request for comment on the collection of standardized social determinants data as a positive for our in-home evaluations. We capture a range of social factors that can impact beneficiary health and are working with our MA plan clients to identify and address these types of needs for their members. The more social determinants data MA plans and CMS have, the better they are able to design programs to meet those needs. We continue to believe the value and independence of our comprehensive in-home evaluations for MA plans is a tailwind. We view our recent announcement that Optum expanded their volume commitment with Signify through 2026 as another very positive sign that they and our broader client base are tapping Signify Health versus insourcing because they recognize and continue to recognize the value they derive from our services. As a result, we believe the insourcing risk of volume is very low. To meet increasing IHE volume demand, in 2021, we grew our network of physicians, nurse practitioners, and physician assistants to over 10,000. As we increase volumes in certain geographic areas, recruiting and credentialing can experience delays. Largely, we're not experiencing the same clinician labor issues being reported more broadly. As we have often said, a significant benefit of our flexible network is that we credential our providers in multiple states, allowing us to deploy them wherever evaluation demand requires, including rural communities. The value of our logistics and routing technology included within our proprietary iPad application makes it easy for our clinicians to do what they value most, spend quality time with patients instead of dealing with administrative issues in a facility setting. Beyond clinicians, technologists are in high demand, and lead time to fill these roles have been extended with elevated compensation packages. To alleviate this challenge, we are opening a technology center in Ireland to recruit and retain technologists in a market plentiful with talent. We have created an Irish legal entity, chosen an office location in Galway, and have been recruiting for key roles. We expect to have a core team in place by this summer. We are excited about the opportunity to have an additional source of qualified talent to add to Signify. In closing, we are very pleased with our 2021 results and many of our accomplishments, which establish a strong foundation to expand upon as we move through 2022 and beyond. When we filed for our IPO a little over a year ago, we outlined a bold vision to drive transformation of the U.S. healthcare system from fee-for-service to value-based care. Our 2021 performance and acquisition of Caravan Health have advanced us in realizing that vision. We simplify participation in highly complex payment programs and enable health plans and providers to successfully transition to value-based payments. We provide comprehensive and highly valued in-home evaluations while facilitating services in and around the home to create synergies between our HCS and ECS businesses. With the addition of Caravan Health, we add further functionality, broader populations, and innovation to our platform to drive increased value for our customers and patients. I'll now turn the call over to Steve to walk you through our fourth quarter and 2021 financial results. Thank you, Kyle, and good morning, everyone. I'm happy to report on our fourth quarter and full- year 2021 financial results. We had another record revenue and adjusted EBITDA year, delivering over 20%+ growth, strong EBITDA performance, margin expansion, and significant cash generation. From a capital perspective, we raised more than $600 million in a successful IPO and very quickly thereafter executed on a refinancing that provided us with even more financial flexibility through better terms and a larger revolving line of credit to support our strategic plans. Strength in our Home and Community Services segment drove performance in the fourth quarter and for the year- ended 2021, reflecting substantial expansion with clients, supporting our belief that clients continue to see significant value in the services that we provide. In episodes of Care Services, we continue to deliver strong savings to our partners across the BPCI program and our Inaugural Commercial clients while ensuring individuals receive excellent care within their episodes. We continue to see the impact of COVID on skilled nursing facilities and inpatient rehab facility utilization due to COVID regulatory waivers put into effect on the public health emergency. Additionally, the Omicron spike in the fourth quarter continues to weigh on program size and savings rate, which is reflected in our 2022 guidance. Over time, we do expect this impact to lessen. As I walk through the results, I'll be referring to the tables that appeared in the earnings press release issued yesterday, as well as the earnings presentation posted on the events page. As you can see in Table 1, we had total revenue in the fourth quarter of $181.4 million, compared to $193.5 million in the same period last year. HCS revenue grew in the fourth quarter of 2021 by 5% to $156.2 million. Total evaluation volume for the fourth quarter was approximately 473,000, including virtual evaluations. The fourth quarter reflected more typical seasonality as we had been expecting and indicating over the course of 2021. Fourth quarter 2020 IHE volume reflected a COVID-related catch-up from earlier in the year when, as previously indicated, in-home evaluations were temporarily paused and virtual evaluations were rolled out. We have great momentum in evaluation volume as we head into 2022. Still on Table 1, fourth quarter 2021 ECS revenue was $25.2 million as compared to $44.7 million the same period last year. The decline was related to the adverse impact of COVID-19 on our program size and savings rate. The Delta and Omicron variants and CMS's automatic elimination of any episode with a COVID diagnosis, even those where patients were asymptomatic or only had mild symptoms and may have had no bearing on the success of the bundle, had an outsized impact on program size. We delivered significant savings for bundles in spite of the ongoing COVID impact, and we have the analytical tools and provider partnerships required to drive even more savings as COVID becomes less prevalent moving forward. Moving to Table 4, total company adjusted EBITDA for the fourth quarter was $40.2 million compared to $38.9 million for the fourth quarter of 2020, reflecting the aforementioned HCS and ECS revenue puts and takes. Back to Table 1, fourth quarter total net income was $32.4 million compared to $0.7 million for the same period a year ago. Our strong operating performance, in addition to the $36.7 million quarterly reevaluation of our equity appreciation right agreements, or EARs, drove net income this quarter. We mark the EARs to market each quarter, and the credit in the quarter reflects the lower value of our stock price at year-end. As Kyle mentioned, we are very excited about the extension of Optum's volume commitments through 2026. In return for the incremental volume, we entered into a floor agreement with Optum that provides for a minimum dollar value in relation to the ultimate settlement of the year. Optum must satisfy the relevant volume minimums over time in order to earn the floor, and as such, at year-end, we did not record a liability related to this instrument. We expect that the floor will become irrelevant as we continue to execute on our strategies, and our progress is recognized in the stock price. There is an accounting requirement for the year to reduce the revenue based on the valuation of the floor when issued and over the term of the contract. We will mark the floor to market going forward, and any changes in valuation will be reflected in the other income or expense line. For 2022, the revenue reduction related to floor will be approximately a full percentage point reduction to reported revenue. We exclude this impact in our calculation of adjusted EBITDA, resulting in no bottom line impact. Turning to full- year results, 2021 was a banner year for Signify Health as we grew the top line 27% while delivering 37% adjusted EBITDA growth and 160 basis points of margin expansion. Results for full- year 2021, the continued overall strength in our Home and Community Services segment, with increasing demand across many clients, driving strong IHE volume of 1.92 million for 2021. Virtual evaluations as a percentage of total IHEs totaled 17% in 2021 as compared to 36% in 2020. We anticipate that virtual evaluations as a percentage of the total will be slightly lower than 17% for the full- year 2022. With client demand at record levels, we are projecting that IHE volume will be between 2.39 million and 2.42 million for the full- year in 2022. Episodes of Care Services results for 2021 reflect the COVID-19 impact on healthcare utilization, savings rate, and discharge patterns reported in connection with the reconciliations received in June and December. As we exited 2021, we were on track for a $6 billion bundled payment program size run rate before COVID exclusions. Taking into account the fourth quarter spike in Omicron and the uncertainty around future variants, we felt it was prudent to forecast additional COVID exclusions for 2022, and now estimate weighted average program size to grow from 2021 levels by between $500 million-$1 billion, depending on the impact of COVID. We expect the savings rate to return to our historical 25-50 basis points range of annual improvement during 2022. With Caravan adding 10 months of revenue from savings generated from over 500,000 ACO lives, we expect the ECS segment to return to strong growth in 2022. Therefore, we are projecting ECS segment revenue, including Caravan, to grow in the mid-20% to low-30% range for the full- year 2022. Moving on, as you can see in Table 2, we ended the year with $678.5 million in unrestricted cash, a substantial increase from $72.6 million a year ago, which reflects IPO proceeds of over $600 million. We funded the cash portion of our $190 million acquisition of Caravan Health on March 1st, 2022 with cash on hand. We ended 2021 with debt outstanding of $338.4 million and $173 million in capacity under our new revolving credit facility. Given our strong cash position at December 31st, 2021, which exceeds our debt levels, we ended the period with negative net leverage. We have tremendous momentum going into 2022 and are providing the following revenue and adjusted EBITDA guidance ranges for 2022, which includes Caravan Health results for 10 months of ownership in 2022. Total GAAP revenue in the range of $948 million-$971 million, and total adjusted EBITDA in the range of $212 million-$222 million. We feel very good about our 2022 outlook and expect margin expansion of 25-70 basis points. Quarterly revenue phasing in 2022 will have some slight differences from 2021, as the Caravan acquisition will only be included for 10 months of 2022, with only one month of actuals in the first quarter of 2022. As a result, total first quarter revenue, including Caravan, will represent 21%-22% of the full- year revenue. As we build the capacity for the full- year record revenue, we expect the first quarter margin to be about 2%-3% points lower versus full- year 2021 margin. Including Caravan, we expect the first half revenue to represent roughly 48%-49% of full- year 2022 revenue, and the second half to represent about 51%-52%. We look forward to integrating Caravan Health into our operations to expand our product portfolio and value-based care payment programs. Now I'd like to turn the call back to Kyle for closing remarks. Thanks, Steve. I'd like to take this opportunity to thank our team at Signify for their positive and compassionate focus on the individuals we serve and all of their contributions to expanding and solidifying our business model in 2021. As mentioned at the beginning of the call, we have a long list of accomplishments of which to be proud. We welcome Caravan Health to the Signify team and look forward to their contributions to help health plans and providers close gaps in care so that people can remain in their homes and enjoy more healthy, happy days. I would also like to thank all of our stakeholders who are on this journey with us for the value we fully expect to generate over the long- term. Now I'll turn the call over to the operator to take your questions. Operator? At this time, I would like to remind everyone in order to ask a question, please press Star followed by the number one on your telephone keypad. We will pause for just a moment to compile the Q&A roster. Your first question comes from the line of Michael Cherny from BofA. Please, Michael, your line is now open. Hi, this is Charlotte on for Mike. Thanks for taking my question. I just wanted to start out looking at the mix of IHEs and in-person versus virtual. Could you provide any more color on that? Just the impact to margin. Yeah. Thank you for your question. Last year was 38%, or two years ago was 38%. Last year we cut that to about 17%. This year for 2022 we didn't really guide to. We think it'll be somewhere slightly less than 17%. But it will still given where we are, what we saw in the first quarter with some of the Omicron spikes and stuff, we're still using virtual pretty heavily. It's somewhere gonna be slightly less than what we did in 2021. From a margins perspective, again, it's more of a revenue. From a margin percent perspective they're very similar in our costs profile. We don't think that's gonna impact our margin percent in a significant way. That's why we're confident in our 25-70 basis points margin improvement for the year that we forecasted. Great. Thanks. Just a follow-up, if you could provide any more color on the visibility into the ECS growth rebound? Yeah. Look, Q4 was we got hit pretty hard with the Omicron viruses. As I said on the call, the challenge with that is that any episode that has a diagnosis of COVID, even if it's asymptomatic and nobody you know or very mild cases, we may have delivered incredible savings on that episode. If it gets a COVID diagnosis, it gets removed from our program size. You know, that's something that we're gonna be working with CMS on as we move forward and hopefully get that re-removed at some point this year. You know, it was a pretty big impact for us with the entire COVID in 2021. We do feel and see that we will start to have some rebound there. We're not going back to, as I said on the call, we don't feel it's prudent to go back to our $6 billion run rate. We don't think it's gonna be that big of a quicker return. We still have that ability, but it's with the carryover from what we saw in Omicron, we're trying to be a little bit more conservative there in saying that we believe that, you know, $500 million-$1 billion of program size will come back in 2022. Great. Thank you. Thank you. Your next question comes from the line of Anne Samuel from JP Morgan. Please, Anne, your line is now open. Thanks so much. Your commentary on the REACH program, you know, was really encouraging around value-based care. I was just wondering how we should be thinking about, you know, what the read-throughs might be for the BPCI program and how you're thinking about that. Yeah, great. Hi, Anne. Thanks. Good question. I would say just a few things. One, CMS has been pretty consistent, and we just delivered a big white paper to them that we've been unpacking for several months with Harvard and Brandeis and UPenn, a bunch of thought leaders talking about the future of value-based care, which is, as they've publicly said several times, integrating ACO and episodes of care. What's important on the ACO front, obviously, it gives you the broad-based population health, total cost of care, big spend under management, but you know, lower overall savings rates potential, whereas the bundles or the episodes obviously attack the specialty care and the post-acute care in a more focused manner. Bringing those two things together and working through attribution problems and building a more sustainable, value-centric infrastructure, you know, to save the Medicare trust, which is under extreme pressure. You know, the CBO said 2026 it might be insolvent. CMS has said by 2030 they want everyone in Medicare in a value-centric contract. What we view, you know, bringing episodes and ACO together and why we did the Caravan deal was to accelerate that, Number 1. With respect to REACH, we're very enthused for two main reasons. One, social determinants and thinking about health equity in a more holistic care model has been in our DNA since day one, and so we are well positioned to bring a really differentiated approach to folks who are interested in participating in the REACH program. Number 2, you know, we've been planning and preparing for direct contracting/total cost of care movement with respect to our R&D and our expansion efforts. We think the Caravan acquisition positions us extremely well for that move into REACH. Frankly, I believe that Signify is the best organization in the country to help CMS achieve its goals of moving more folks into, or all folks in Medicare, towards value-centric contracts by 2030. That's really helpful. Thank you. Maybe just one on Caravan. Can you help us understand, you know, as we think about the contribution to your numbers this year and going forward, how should we be thinking about, you know, growth and margin expansion opportunity for that business over time? Yeah. Look, we're excited. It's very much like the episodes business is as the savings rates improve over time, a lot of that's gonna drop to the bottom line. That's where we're excited about the margin expansion. It's one of the things that I had mentioned on the call. Like, we think, you know, heading into 2023, we could potentially double the EBITDA contribution from Caravan for those exact reasons. That's great. Thanks, guys. Yep. Thank you. Your next question comes from Sarah James from Barclays. Please, Sarah, your line is now open. Thank you. I wanted to clarify the comments you made earlier about not experiencing the same labor pressures as the rest of the industry. Does that mean that there's no step down in labor cost assumed in your 2022 guide? Yeah, we've been very fortunate. I'll clarify the first comment, and then I'll let Steve talk about the step down in cost point. Our model is one distributed, right? We have nationwide access. We credential clinicians in multiple states, move them around when and where, you know, volume kind of dictates as we launch and expand our services. That flexibility model has been great, you know, for us. Like, it's not, you know, folks can sign up for shifts when they want. They can move to different states, different parts of the year. I would say it's been a tailwind for us in the pandemic and brought us a bunch of new talent, which is why we've been able to successfully scale and you know hit all the capacity constraints that we talked about, Number 1. Number 2, clinicians are turning to us because we're allowing them to spend an hour of really high quality time focused on care with individuals, right? They're divorced from all of the administrative burden that they face so often if they're running their own practice or working in a bigger health system, dealing with claims, dealing with getting bills paid, dealing with scheduling, dealing with all the prior authorization workflow. With us, because of our you know technology suite, they wake up, have our iPad application, you know, that we've built out with all the logistics and routing technology that allows them to go, you know, throughout the day, spending time and, you know, an hour inside these homes with real quality time helping to diagnose folks and then connect them back to care. We feel very good about that. Steve, I'll let you talk about just how we've accounted for labor in the model maybe. Yeah. On the, you know, again, I ask that a lot on the inflationary pressures and so, you know, like every company, we have challenges in that area. I think, as Kyle said, we've got a very flexible model that's allowed us to manage that, and it's a great part of the model. You know, we have areas where there's significant demand, and we'll do special incentives and things like that. We haven't seen significant pressures that are, you know, impacting the P&L or anything that we can't manage. That's why we, again, are confident that we can do the 25-70 bps of margin expansion despite any pressures. We also mentioned, you know, we've seen quite a bit of pressure on the technology side. One of the areas that we've been able to go and find more talent is opening up the Ireland office. We expect that to be a big part of our go forward opportunity as well in that area. Great. If I could just one more. Can you give us a little insight on how you think about the adoption curve within your existing client base, maybe how you're seeing that trend from 2021- 2022? Then as you think about moving out to CMS's goals in 2030, how much opportunity there is to capture more business within your existing client base? Yeah, it's a great question. I would say that, you know, what drove us to do Caravan was our client base. You know, we were listening to them. They mentioned both the payers in the health system said, Look, we need a multi-payer solution for me to go in and actually bridge this gap between the health systems and the health plan, and they view Signify as a key enabler of that. I think there's substantial growth opportunity inside our existing client base. Frankly, it's where we're focused on initially, cross-selling and combining episodes, total cost of care, and bringing that multi-payer approach. You know, the issue, and what I mean with multi-payer, if you show up with a single payer contract at a health system with its own set of guidelines and rules and reporting and data ingestion, you've got a percentage of panel issue, right? You need somebody, someone like a Signify that's gonna connect the dots with all of our payer contracts, standardize a lot of that workflow, have consistent, you know, unified reporting, and allow us to offer a more integrated approach on the data and analytics side, for the providers that are actually engaging in care. What we anticipate doing is bridging all of those, you know, strong ACO connection and relationships that Caravan's built out that takes a genuine total cost model, bringing in our episode infrastructure, and then working with our plans, to bring that multi-payer approach where obviously CMS is the biggest payer, and is the biggest participant in the bundled payments in the ACO program. Tying all that together and growing that into our existing, you know, very large, very scaled, very successful, very high NPS, health plan business, that we have on the in-home side is where we're gonna be focused over the next several years. Great. Thank you. Yeah, thank you. Thank you. Your next question comes from the line of Kevin Caliendo from UBS. Please, Kevin, your line is now open. Thank you. I wanna understand a little bit, your revenue per visit trends. Your virtual visits are gonna be down. What are you assuming for price per IHE visit, for 2022? Do you expect it to trend up, trend down? Yeah. It's going to trend up, although there's a couple factors if you just aggregate it and look at it in total that's gonna say it's relatively flat. There's two things. The year impact is gonna hit the HCS side, and so that's gonna impact that number. We have a little bit of a mix impact as well in total, where some of our you know incredible volume that we're getting from is coming from some clients with a little slightly lower pricing. You know that's really in an aggregate, you're gonna see it's relatively flat, but when you look at it by client, you're gonna see that it continues to increase. So, so- I would say the, you know. Oh, I'm sorry. Yeah, sorry, Kevin. Yeah, the other two things that you'll see start to phase in there, and we mentioned this on the last call. We've got more diagnostic and preventative service device revenue coming in as we've got more diversified devices going into the mix this year. Then a big initiative that we've been doing for several years, but that our clients are very focused on, is returning to care. Getting folks booked back with a specialist or booked back to their primary care doctor, sending all of that information over digitally, we see that as a big synergy with you know, Caravan too, because we'll have all that digital connectivity into these health systems. That return to care expansion and that we've talked a lot about will be, you know, phased into that mix as well. All right. That's helpful. I'm guessing in the metrics, would that be United and sort of the re-up with United, did that have an impact on this? There wasn't any price changes there, but you know, obviously there's a significant volume coming from there. Again, our higher volume clients are typically gonna have slightly lower pricing, and so you're gonna get some mixed component in there. Fair enough. One quick follow-up. You had said you've been working with CMS to get the COVID diagnosis headwind removed. Any chance there's potential for retroactive adjustments? Yeah. We're in open dialogues with them right now. You know, I don't think we're in a spot to comment on. But they certainly have in the past on retroactive on other things. They're very reasonable. They're very data-centric. I would also mention our health system clients are bringing this up too. This isn't just us, you know, mentioning this. The health system clients are, you know, they're rightfully frustrated. As Steve mentioned, if someone's in for an episode, they go through the procedure, the health system does everything right. They manage the post-acute appropriately. They get them back to their home. Then on day 89 of the episode, they asymptomatically test positive with COVID, they get bounced out. That's super, you know, frustrating for a health system that's investing millions and millions of dollars to do genuine care redesign. We're just in another phase of the pandemic too. I would say that CMS has been very reasonable, very data-centric, and a tremendous partner on this front. We're very hopeful, I should say, that we'll be able to move past the current kind of policy here in short order. That's great. If I can ask one last quick one, and I apologize for asking three. Is the cadence for this year different than you would normally expect? I mean, we don't have a ton of history to go back on, and I'm just wondering if there was anything specific around 2022 in terms of the cadence or if Caravan is impacting the cadence a little bit. Just any color on how we should think about that, you know, even going forward beyond 2022. When you're talking about cadence, are you talking about kind of the quarterly phasing? Yeah, the quarterly cadence. I'm sorry, I didn't make that clear. Yeah, as I mentioned in the call, we think obviously because the way the Caravan, you know, it's gonna be more back half loaded because we're only gonna have 10/12 of the year included. Got it. Only one month in quarter one. That's why it's a fairly typical, you know, you're gonna have your ETS with Q2 and Q4 that are gonna be the higher quarters, just because that's when we get the recon. I would say the HCS is relatively, you know, consistent. It's gonna be probably a little bit less. That's why in total, we said, you know, first quarter just to get everyone grounded, we think it's gonna be, you know, 21%-22% of the total. Then, you know, the first half, 48%-49%, and then, you know, we should be kind of back. Q4 will be our softest quarter just because of the way that the HCS volume typically takes place. You know, other than in the past, we've had some of the dynamics change because of the COVID impact, and nothing really to call out on that this go around. We also called out that you know, margin percent. You know, if you look back at 2019, 2020, 2021, you know, 2022 is not gonna be any different. Our margin percentage is typically the lowest percent to start the year, and that's just because we're ramping up and building all the capacity. Just wanted to call that out as well. That's really, really helpful. Thanks, guys. Yep. Great question. Thank you. Thank you. Your next question comes from the line of Cindy Motz from Goldman Sachs. Please, Cindy, your line is now open. Thanks. Congrats on the quarter, and thanks for taking my question. I just wanted to follow- up a little bit on Kevin's question about the implied, you know, average revenue per visit. I'm getting like about $325 for this quarter, so it usually goes up first quarter. Steve, I was just wondering, like, do you expect the same kind of ramp that we maybe saw from fourth quarter 2020 to first quarter 2021, you know, and sort of maybe flat, you know, for the year overall? Then my second question was just on ECS. To get to that 20% revenue that you're talking about, it looks like we do have to look at more the higher end of the sort of average program size guidance as well as the ECR, you know, the savings rate. Am I right about that? Thanks. Yeah. Just to reiterate on the first question back to the HCS. You know, it's gonna be relatively flat as I mentioned. If you just do the total calculations, if we looked at it by client, you're gonna see that it continues to rise. And again, it's really two things, the impact from the EARs, 'cause that's just taking revenue straight out of HCS, and it's a technical accounting. We back it out of EBITDA, so there's no impact there. And then the mix issue. And it's really those two issues. There's no other dynamics going on there. Other than us, you know, as Kyle brought up, you know, we continue to have additional penetration with our devices. We're adding new devices and more return to care. We feel really good about the direction that that's heading. Then on the ECS kind of range that we put there in the mid-20s to low 30s. Look, we ran a bunch of different scenarios there. Just to make sure that we could have, you know, some flexibility on program size, on savings rate and folding in Caravan into the mix. We feel comfortable where we're at now. Obviously as the quarters move on, we'll report out on how things are trending. Obviously some of these things that we've been talking about on what happens with CMS and the announcements coming there could impact that as well. We'll keep everyone well informed. Okay. Thanks. That makes sense. Just if I could have one more follow-up. You know, in terms of the EBITDA margins for the segments, you know, obviously HCS is, you know, doing pretty well, and looks like it hit already like, you know, 30%-31% margins there. And the, you know, ECS is, you know, certainly more challenging. Do you expect, you know, the sort of ECS margin rate to, you know, improve over the next year? You know, and then I also too, I guess HCS to remain stable, or how do you see the margins, the segment margins going? Thanks. Look, on the ECS side, there's one thing that's in particular that's really driving that one. Obviously, as you know, adding Caravan to the mix is nice. Adding as the savings rates bounce back, we're gonna see that margin improve because that's gonna drop straight to the bottom line. But I'd like to call out that we still are making pretty significant investments in the commercial side, and that's one that we've been saying is like, we're really gonna start to see that in the 2023, 2024, 2025 return on investment there. That's one that we're gonna have another year, I would call it, another year of investment on the ECS side, but we look to break even in 2023. Okay, thanks. Makes sense. Thank you. Your next question comes from the line of Jessica Tassan from Piper Sandler. Please Jessica, your line is now open. Hi. Thanks for taking the question. I just wanted to ask one on Caravan. It's our understanding that they've consolidated from kind of 12 collaborative ACOs in 2020 to 6 in 2022. Can you just help us understand when and why that consolidation occurred? Just how are you thinking about ensuring collaboration at the local level, given the geographic dispersion of some of these ACOs? Thanks. Yeah, great questions. That consolidation was one of the things that has us most excited about doing the deal, and frankly is one of the most innovative things that they've pulled together. What they did in collapsing the 12 down to 6 to 5 was pool more risk, right? It wasn't that they lost clients, they were just taking the existing clients and putting them in these bigger collaborative ACOs. They are regionally centric. And there's a lot of engagement and participation and coordination in those regions where they all sit. The purpose of the collaborative is just like an insurance company. As you take more lives on, you can shield yourself from downside risk. You know, the whims of any one particular hospital health system, you know, in one particular quarter aren't gonna impact the overall collaborative. When they go in it together, it provides a more stable, consistent and balanced program. Frankly, it's the innovation that Caravan pulled off that's helping to spread the total cost of care model throughout so much of the country. We were very enthusiastic about that innovative approach that they pulled off, Number 2. Number 2, they have a big technology component of their business, and it was again, one of the things that had us most excited called Caravan Coach. It's a overlay face sheet that sits inside the provider workflow that notifies and alerts them on the most urgent and emergent things they need to do. Each and every month, they are learning from surveillance throughout the entire ACO network that they're managing in all of the collaboratives, how to drive more efficiency, more effectiveness, and to drive a better provider and patient experience. They are actively in there coaching folks. They're actively in there doing change management inside the health systems. You know, technology is how they enable and power that, but they very much have a strong account management and partnership model with these health systems to help drive performance. That was very appealing to us. I've said many times that I think technology is absolutely necessary but not sufficient to drive real impactful change in healthcare. What we're most excited about, and we've heard from several of the Caravan clients, you know, already, is Signify bringing that nationwide network of clinicians, bringing the post-acute experience, bringing the ability to do condition capture, which is big in the ACO market now. We're gonna turbocharge a lot of these resource strapped health systems to perform even better inside their ACO contracts, which I think one, will drive shared savings, but number two, will help us expand and sell more health systems that are always looking for contracts with payers too. Signify, again, can bring that multi-payer contract chassis. We're very excited about the future and what we're gonna be able to connect here. The technology assets and the team that we picked up from Caravan, you know, after a year-long diligence process inside the total cost of care space, we felt like it was the absolute, you know, best fit for Signify and where CMS and our payer clients and our health clients are going in the future. That's really helpful. Just a quick follow-up. It sounds like Signify plus Caravan are really well situated for ACO REACH. Interested if you expect that, participation in ACO REACH to be in addition to or instead of participation in, MSSP? Thank you. Yeah, good question. I think, Number 1, it's too early to tell. You know, the announcement obviously just came out last week. I would say, though, I expect some or right now, Caravan has some clients in basic, some in enhanced. Our first priority is to move as many over to enhanced as possible, more downside risk, better upside for us and the clients in the enhanced models. We're big fans of the enhanced model. Number 2, we're focused obviously on shared savings this year and maximizing, you know, better patient outcomes while driving shared savings for the clients. I think we're gonna go, you know, specifically client by client, both our episode clients today, the existing ACO clients, and take a look at enhanced versus ACO REACH and what makes the most sense for them. I don't think it's gonna be the same for everybody. There's a lot of nuance. Every health system is different. What we have is a great standardized platform that regardless of REACH or enhanced is going to be able to drive success for these folks. We're you know, diving in. You know, we had our first session yesterday, I'm sorry, with the Caravan team going through all their clients, our clients, and starting to map out a strategy of how to best drive success for each of them. What I'm most excited about is ACO REACH gives us more optionality, right? It's yet another value-centric program that we're gonna be able to expand and drive performance into. That's great for the health system clients who are nuanced and each of them very different, with respect to their skill set and their competencies and how they wanna perform in diabetes care. Thanks, guys. Thank you. As a reminder, if you would like to ask any question, please press Star followed by number one on your telephone keypads now. Your next question comes from George Hill from Deutsche Bank. Please, George, your line is now open. Good morning, Kyle and Steve. Thanks for taking the question. My ACO REACH question was just asked, so I can put that on the back burner. I guess as it relates to the HCS segment, Kyle, I think there's still a lot of investor concern about the long-term horizon of this business. I think a lot of investors are looking for a regulatory clearing event to kinda like bless the long-term sustainability of the HCS business. I'd like to hear what you think about that. I kinda thought that the early rate notice from CMS talking about social determinants of health could have been that. You know, there do seem to be some investor questions about it. Would just kinda love to hear how you think about it and kinda what removes kinda that negative sentiment that I think is serving as a cap on valuation right now. Yeah. You know, great question. So we have been in constant dialogue with CMS for years. There's been nothing, just to be clear, in the rate notice for years about years and years about anything to do with major overhauls or risk adjustment or any pressure on the In-Home segment. We deeply believe it's a big overreaction in the market, and couldn't agree more that you know, it's an unnecessary overhang, Number 1. Number 2, we have been in great conversations with CMS, where they've been direct with us saying, Look, we are big supporters of In-Homes. What we wanna see is continued more follow-on care, more social determinants of health engagement like you all are doing. That roadmap of what we've built into is exactly what they are doing. Then Number 2, on the growth side, we've also been in talks with CMS, and we just got into the MSSP program about expanding In-Home and their viability to other value-centric programs. We will be launching In-Home services alongside those Caravan ACOs, right? It's going to be a big differentiator of how we drive better shared savings, better condition capture, and better engagement for individuals in the same way that Signify has always been doing it, looking at the entire continuum of care from the homes all the way to the facilities. You know, I think it's a huge overreaction that folks think that some massive changes are coming to risk adjustment. None of our plan clients are concerned with it. They've all been, you know, really engaged with us and focused on how to make sure that we're maximizing when we find a condition, doing something that's great for the individuals, whether it's a de novo diagnosis or getting them back to a specialist or closing out a food insecurity. There is nothing more sacred than getting to go into an individual's home and seeing the reality of what they're facing on a day-to-day basis. CMS is thrilled that it's a free benefit that, you know, Medicare beneficiaries are getting as a part of the Medicare Advantage program. All of our conversations with CMS have been on how to expand that free benefit to other parts of the Medicare population. As I just mentioned, we're gonna be doing that through our MSSP engagement. We're seeing no regulatory pressure at all and think it is a you know a complete you know exaggeration that there's some boogeyman hiding out there that's gonna overhaul this part of the business. Yeah. The proof point really from our clients' viewpoint is just the amount of volume that they continue to give us. Like, you know, Q4 was a incredible quarter for us. It's 'cause that's usually a big drop-off for us as we wind down the year. We still actually grew over 2020, which had the big COVID impact, where we were doing a big percentage of our volume in Q4. As everyone is seeing, you know, we're guiding to about 2.4 million evaluations in 2022. Really getting a lot of momentum with our clients to drive more and more IE volume. Yes. To Steve's point, every single one of our clients is sitting down and asking how we can get into more homes and do more in the home. That's across the board. There's no signs of this business slowing down. If anything, again, we're having conversations about how to take this into managed Medicaid, commercial populations, other group accounts. They're including, you know, our services and our holistic care model in their bids for different group accounts. We are very bullish on the continued growth and expansion of this business. That's great, Kyle. I think you guys framed the answer better than I framed the question, but I appreciate it. Thank you. Thank you. We currently have no further questions. I will hand over back to Kyle Armbrester for any final remarks. Great. Thank you, everybody, and thanks to the entire team for a great 2021. Thank you guys for the participation in the call and your continued interest in Signify Health. If you have any additional questions, please reach out to Jennifer. Have a great day. This concludes today's conference call. You may now disconnect your lines.